MedTrace Logo

An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B

NCT01667432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 141

Last updated 2017-04-10

Study results available
· View outcomes & findings →

Summary

This prospective, multicenter, observational study will evaluate on-treatment predictors of response in patients with HBeAg positive or HBeAg negative chronic hepatitis B receiving treatment with peginterferon alfa-2a (PEGASYS®) in accordance with local labeling and the summary of product characteristics. Data will be collected from patients for the duration of their treatment and for up to 24 weeks thereafter.

Conditions

  • Hepatitis B, Chronic

Interventions

BIOLOGICAL

Peginterferon alfa-2a

Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-08
Primary Completion
2014-08-12
Completion
2014-08-12

Countries

  • Bulgaria

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01667432 on ClinicalTrials.gov